EMJ Oncology 9 [Supplement 4] . 2021

OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the worst prognosis and highest mortality. This is because of its resistance to common chemotherapeutic agents, vague and non-specific symptoms, and the lack of effective screening strategies for early detection. However, new research has suggested that poly(ADP-ribose) polymerase (PARP) inhibitors could potentially transform the treatment landscape of advanced ovarian cancer.